rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BIVI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Biovie CEO Cuong V Do buys $2,492 in company stock
      3h agoInvesting.comBIVI
      BioVie shareholders approve director elections and equity plan at annual meeting
      Nov 10Investing.comBIVI
      BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases
      Nov 10Yahoo FinanceBIVI
      BioVie identifies two Long COVID patient groups with distinct responses to bezisterim

      BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said new biomarker analyses from its Long COVID trial identified two patient groups that responded differently to its drug bezisterim. The company said the findings could inform the design of future Long COVID studies. Results from the ADDRESS-LC...

      Nov 9Yahoo FinanceBIVI
      BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
      Nov 9Yahoo FinanceBIVI
      BioVie to raise $4.74 million in registered direct offering
      Nov 4Yahoo FinanceBIVI
      BioVie raises $4.74 million in registered direct offering
      Nov 4Investing.comBIVI
      BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
      Nov 4Yahoo FinanceBIVI
      BioVie to present new Long COVID biomarker data at Nice conference
      Nov 2Yahoo FinanceBIVI
      BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
      Nov 2Yahoo FinanceBIVI
      BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
      Oct 26Yahoo FinanceBIVI
      From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
      Oct 24Yahoo FinanceBIVI
      BioVie reports positive Phase 2 Parkinson’s data for bezisterim

      BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological...

      Oct 20Yahoo FinanceBIVI
      BioVie reports positive bezisterim trial results in Parkinson’s
      Oct 20Investing.comBIVI
      BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
      Oct 20Yahoo FinanceBIVI
      BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
      Oct 19Yahoo FinanceBIVI
      BioVie to present Long COVID and Parkinson’s trial results at American Neurological Association meeting

      BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson’s disease, at the American Neurological Association’s annual meeting in San Diego. The company said both abstracts were accepted as poster...

      Oct 14Yahoo FinanceBIVI
      BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
      Oct 14Yahoo FinanceBIVI
      New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global

      Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p. ET broadcast reaching audiences across the United States, Latin America and MENANEW YORK CITY, NY / ACCESS Newswire / September 26, 2026 / , the financial-media platform for public companies, pre-IPO companies and entrepreneurs, today announced that Show 773 will air tonight at 6:30 p.

      Sep 26Yahoo FinanceBIVI
      New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

      BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

      Sep 19Yahoo FinanceBIVI
      Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

      ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 19, at 7:00 p.

      Sep 18Yahoo FinanceAENTBIVI
      BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow (NASDAQ:BIVI) 2026-09-17

      2026-09-17. The following slide deck was published by BioVie Inc.

      Sep 17Seeking AlphaBIVI
      Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results

      BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin resistance across neurological disordersORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar on September 23, 2026, at 11:00 a.The exclusive event will feature BioVie President and CEO Cuong Do

      Sep 16Yahoo FinanceBIVI
      What's Going On With BioVie Stock on Tuesday?
      Sep 15BenzingaBIVI
      BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population

      BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.

      Sep 15Yahoo FinanceBIVI
      Why is BioVie stock sliding today?
      Sep 15Investing.comBIVI
      BioVie reports phase 2 long COVID trial results
      Sep 15Investing.comBIVI
      BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

      Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m. today, September 15, 2026, to

      Sep 15Yahoo FinanceBIVI
      BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

      Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the Company will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial (NCT06847191

      Sep 14Yahoo FinanceBIVI
      BioVie advances Parkinson’s Phase 3 development program with FDA engagement

      BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson’s disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson’s disease...

      Sep 8Yahoo FinanceBIVI
      BioVie Announces Update to Parkinson’s Phase 3 Development Program

      CARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developin...

      Sep 8Business InsiderBIVI
      BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

      Last Patient Last On-Site Visit Completed with Topline Data Release Targeted September 2026CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed. The Phase

      Aug 31Yahoo FinanceBIVI
      BioVie completes final patient visit in Phase 2 Long COVID trial

      BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based...

      Aug 31Yahoo FinanceBIVI
      Biovie CMO Joseph Palumbo buys $10,460 in common stock
      Aug 29Investing.comBIVI
      Biovie director Amy Chappell acquires $1,570 in BIVI common stock
      Aug 29Investing.comBIVI
      Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock
      Aug 29Investing.comBIVI
      BioVie Inc. CEO Cuong V Do buys $31,636 in company stock
      Aug 29Investing.comBIVI

      This is the newest page. Registered accounts read further back.